Program
HRS-8080
A development code. Also written as “HRS-8080 Tablet”, “HRS-6209 in Combination with HRS-8080” and “HRS-6209 in Combination with HRS-9813 and HRS-8080”.
In Jiangsu HengRui Medicine's pipeline, SERD
. Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 1310 open or running | phase 3since Jun 9, 2025 | Dec 16, 2021 | Feb 2027phase 1 · NCT07876596 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-8080
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2021First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05189717 · 156 planned · China
- Dec 4, 20232 phase 2 studies in Breast NeoplasmsNCT06222879, NCT06167694
- Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
- Sep 25, 2024Phase 1 study in Breast NeoplasmsNCT06619873 · 24 enrolled · China
- Nov 6, 2024Phase 2 study in Breast NeoplasmsNCT06679036 · 300 planned · China
- Jun 9, 2025Phase 3 study in Breast NeoplasmsNCT07024173 · 240 planned · China
- Nov 13, 2025Phase 1 study in Breast NeoplasmsNCT07229560 · 16 enrolled · China
- Dec 22, 2025Phase 1 study in Breast NeoplasmsNCT07320521 · 6 enrolled · China
- Jan 8, 20262 phase 3 studies in Breast NeoplasmsNCT07354022, NCT07349069
- Jan 29, 2026Phase 2 study in Advanced Unresectable or Metastatic Breast Cancer of AdultsNCT07389733 · 180 planned · China
- Oct 2, 2026Primary completion moved from 2026-12 to 2027-08Date moved laterphase 3 · +8 months · NCT07024173
- Oct 9, 2026Phase 1 study in Breast NeoplasmsNCT07876596 · 18 planned · China
Ahead
- Feb 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07876596
- Aug 2027Primary completion: phase 3 study in Breast NeoplasmsNCT07024173
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
- Dec 2028Primary completion: phase 2 study in Advanced Unresectable or Metastatic Breast Cancer of AdultsNCT07389733
TargetBeta
“SERD”the company's pipeline, read by Claude · source
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07876596Breast Neoplasms · China | 1 | Not yet recruiting | Feb 2027 | 18 |
| NCT07389733Advanced Unresectable or Metastatic Breast Cancer of Adults · China | 2 | Recruiting | Dec 2028 | 180 |
| NCT07349069Breast Neoplasms · China | 3 | Recruiting | Dec 2030 | 5,500 |
| NCT07354022Breast Neoplasms · China | 3 | Recruiting | Dec 2028 | 912 |
| NCT07320521Breast Neoplasms · China | 1 | Completed | Jan 28, 2026 | 6 |
| NCT07229560Breast Neoplasms · China | 1 | Completed | Dec 31, 2025 | 16 |
| NCT07024173Breast Neoplasms · China | 3 | Recruiting | Aug 2027 | 240 |
| NCT06679036Breast Neoplasms · China | 2 | Recruiting | Oct 30, 2026 | 300 |
| NCT06619873Breast Neoplasms · China | 1 | Completed | Nov 13, 2024 | 24 |
| NCT06555068Breast Neoplasms · China | 2 | Recruiting | Dec 2027 | 528 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Oct 31, 2026 | 350 |
| NCT06167694Breast Neoplasms · China | 2 | Recruiting | Jun 2026 | 146 |
| NCT05189717Neoplasm Metastasis · China | 1 | By invitation | Oct 31, 2024 | 156 |
How it is read
Names in the registry
- “HRS-8080”, 3 entries
- “HRS-8080 Tablet”, 3 entries
- “HRS-6209 in Combination with HRS-8080”, 1 entry
- “HRS-6209 in Combination with HRS-9813 and HRS-8080”, 1 entry
- “[14C]HRS-8080”, 1 entry
Codes read as this program: HRS8080.
Conditions, from the studies’ own filings
- Breast Neoplasms, 12 studies
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.